Myelodysplastic Syndrome
News
FDA grants mAb orphan designation for MDS
The US Food and Drug Administration (FDA) has granted orphan drug designation for BI 836858, an anti-CD33 monoclonal antibody (mAb), in the...
News
Model illustrates progression to MDS, AML
Researchers say they have created a model that shows the step-by-step progression from normal blood cells to acute myeloid leukemia (AML). The...
News
Genetic profiling can guide HSCT in MDS, team says
Genetic profiling can be used to determine which patients with myelodysplastic syndrome (MDS) are likely to benefit from allogeneic hematopoietic...
From the Journals
MDS gene mutations predict response to HSCT
Genetic mutations in blood samples may predict outcomes and guide treatment for patients of all ages who have myelodysplastic syndrome and are...
News
Azathioprine may increase risk of MDS, AML
Results of a large, retrospective study suggest that taking azathioprine, a drug commonly used to treat autoimmune disease, may increase a person’...
News
Targeting disease stem cells in AML, MDS
The cell surface molecule CD99 occurs more frequently than normal on stem cells responsible for acute myeloid leukemia (AML) and myelodysplastic...
From the Journals
Clonal hematopoiesis increases risk for therapy-related cancers
Small pre-leukemic clones left behind after treatment for non-myeloid malignancies appear to increase the risk for therapy-related myelodysplasia...
Conference Coverage
PERSIST-2 might allay some concerns about pacritinib in myelofibrosis
SAN DIEGO – Late-breaking results from the phase III PERSIST-2 trial may ease at least some safety concerns surrounding the use of pacritinib in...
Conference Coverage
Adding epoetin alfa to lenalidomide boosted myelodysplastic syndrome responses
SAN DIEGO – Dual therapy with lenalidomide and epoetin alfa was safe and led to freedom from transfusion significantly more often than...
News
Study reveals potential therapeutic targets for MDS
Preclinical research has revealed potential therapeutic targets for myelodysplastic syndromes (MDS). Investigators found evidence to suggest...
Conference Coverage
MDS patients with mutated IDH2 benefit from enasidenib
Photo courtesy of ASH SAN DIEGO—Daily treatment with enasidenib monotherapy in patients with mutated IDH2-positive myelodysplastic syndromes (MDS...